Abstract More and more companies are advertising and selling genetic tests directly to consumers. Considering the ethical, legal, and psychological concerns surrounding genetic testing in minors, a study of companies' websites was performed in order to describe and analyze their policies with respect to this issue. Of the 29 companies analyzed, 13 did not provide any information about this matter, eight companies allowed genetic testing upon parental request, four companies stated that their website is not directed to children under 18 years, and four companies suggested that in order to be tested, applicants should have reached the age of legal majority. If private companies offer genetic tests which are also offered in a clinical setting, can they be expected to adhere to the existing clinical guidelines with regard to these tests? If so, a certain ambiguity exists. Many companies are emphasizing in their disclaimers that their services are not medical services and should not be used as a basis for making medical decisions. Nonetheless, it remains debatable whether genetic testing in minors would be appropriate in this context. In line with the Advisory Committee on Genetic Testing, the Human Genetics Commission addressed the problem of non-consensual testing and recommended not to supply genetic testing services directly to those under the age of 16 or to those not able to make a competent decision regarding testing.
Introduction
Advances in genetic knowledge and technologies have increased the possibilities of testing asymptomatic minors for late-onset diseases, carrier status or susceptibility to common complex disorders. These developments have raised concerns about the ethical, legal and psychological implications of performing genetic tests in healthy children and adolescents. Many professional associations have issued guidelines and position papers to address the issue of genetic testing in asymptomatic minors in a clinical context [1] . In general, these guidelines recommend that the availability of medical intervention is necessary before predictive genetic testing should be performed in asymptomatic minors. In order to protect the privacy and confidentiality of genetic information and the minor's right not to know [2] , it has been advanced that testing asymptomatic children should be postponed until a minor can participate in the decision-making process [3] . It has also been argued that testing minors potentially creates serious social, emotional, psychosocial and educational consequences for the child and his family [4] .
More and more companies are advertising and selling genetic tests directly to consumers (DTC) [5] . Such DTC genetic testing can be understood as including two related aspects: firstly, the advertising of genetic tests directly to consumers; and secondly, the direct access or ordering of genetic tests without the intermediate of a health care professional from the traditional health care system. The types of genetic tests being offered are extremely varied and include those that offer information regarding paternity, ancestry, health enhancement (nutrigenetics, dermatogenetics), drug response (pharmacogenetics), susceptibility testing for common complex genetic disorders (cardiovascular diseases, hereditary hemocromatosis, osteoporosis, type 2 diabetes…), as well as fetal gender tests (from 5 weeks on). Furthermore, some companies are offering ''genetic profiles'' which involve testing hundreds of thousands of single nucleotide polymorphisms (SNPs), the results of which are claimed to provide personal information regarding susceptibility to many different disorders. Finally, it should be noted, that some companies also offer genetic tests that are commonly offered in clinical genetics centres, such as those for monogenic disorders like cystic fibrosis and Tay-Sachs.
While proponents of DTC genetic testing argue that the benefits of offering such services will include increased access, and greater consumer autonomy, [6, 7] critics point to several potential risks associated with this type of service. Among others, concerns have been raised with regard to the clinical validity and utility of the genetic tests being offered [8] . Apprehensions have also been presented regarding the availability and quality of genetic counseling, the qualifications and impartiality of counselors, the effectiveness of telecounseling and the validity of the informed consent process [9] . Additional concerns revolve around the idea that the provision of genetic tests outside the health care system may consequently lead consumers to visit health care professionals (as a follow up to the genetic test results) and result in an overconsumption of health care services. Finally, the lack of regulatory control over DTC genetic testing services has also been raised as being an important problem [10, 11] .
Above and beyond the worries already mentioned, an additional unease remains: what about the children? What protection is available when dealing with minors in the context of DTC genetic testing services? It has been reported that some companies offering direct-to-consumer genome scanning services accept requests to process samples from minors [12] . Since this earlier contribution only analyzed five companies offering specific services (testing of a large number of SNPs, or genome scans), we provide herein, a more complete overview of the current policies regarding genetic testing in minors based on the information found on companies' websites.
Methods
The companies included in this analysis were obtained from a list published by the Genetics and Public Policy Center (Johns Hopkins University, November 2008) [13] . Thirty-five companies were included in this list, and were considered companies which offer ''tests and test interpretation directly to consumers rather than through the traditional model of health care provider-offered genetic tests.'' [13] . Only companies offering health-related genetic tests that are not explicitly prenatal in nature were included in the analysis. Companies exclusively offering paternity, genealogy, or ancestry tests, as well as those offering DNA matching services (for the main purpose of finding a romantic partner) were excluded. The entire content of the companies' websites, including their consent forms, terms of services and privacy policy statements were analyzed in December 2008. All statements or policies found on the websites and addressing the issue of genetic testing in minors were listed, analyzed and categorized. Every website was reviewed independently by PB and HCH.
Results
Websites from 29 companies (Table 1) were analyzed. Of the original set of 35 companies considered, one company had ceased its activities (Smart Genetics), one company offers only fetal gender testing (ACU-gen Biolabs), one company offers only prenatal diagnostic services (Niagen) and two companies offer only DNA matching services (GenePartner, Scientific Match). Health Tests Direct was also excluded from the analysis because the company sends consumers to a 'blood draw center' located as close as possible to the consumer's home, and the different types of tests offered change depending on each ''blood draw center''.
The information presented on companies' websites regarding the possibility of performing genetic tests in minors, was grouped into one of four categories: (1) companies which do not provide any information on this issue (Table 1 Table 2 ). Although some companies (e.g. 23andme, DNA direct) do acknowledge that their services are not ''designed or intended to attract children under the age of 13'', in the 
Discussion
Our findings suggest that certain companies appear to have an awareness of some of the social, ethical and legal issues pertaining to genetic testing in minors. However, our results also demonstrate that other companies challenge the ethical framework of protecting children as they are willing to provide genetic testing in a pediatric population. Because of the sensitive nature of genetic information, the right to autonomous decision making and self-determination, confidentiality and privacy issues, we feel it is important to take specific notice of direct-to-consumer genetic testing issues for minors. Clinical guidelines focusing on genetic testing in minors have emphasized that the best interest of the child is paramount and that perceived benefits and risks of testing must be carefully weighed when considering a genetic test in minors. In the context of a genetic test for a late onset disorder (e.g. BRCA), testing has only been recommended when ''established, effective, and important medical [14] can be offered or when testing ''provides scope for treatment which to any essential degree prevents, defers or alleviates the outbreak of disease or the consequences of the outbreak of disease'' [15] . The rationale behind this option is that predictive and presymptomatic testing for adult-onset disease ''should be delayed until the person is old enough to make an informed choice'' [16] . The same notion applies to carrier testing, where it has been advanced that ''For carrier status for conditions that will be important only in reproductive decision making, testing of children should be discouraged until the child is able to participate fully in the decision to be tested'' [17].
In the case of presymptomatic and predictive genetic testing for conditions which manifest in childhood, the current policy depends on whether this condition can be effectively treated or prevented. If preventive or therapeutic measures are available, ''there are good reasons to comply or to actively bring up the possibility of a test. However, if the preventive and therapeutic measures will be deferred to a later time, the justification for immediate testing is less compelling and careful, supportive counselling will often be appropriate whether or not testing happens at that time'' [18] . When no treatment or prevention is available, ''there are both benefits and risks, and usually neither the benefits nor the risks completely outweigh each other. Genetic testing could be considered if this would be to the psychological or social benefit of the child and his family'' [18] . Since the companies studied offer a wide variety of tests, many of which have yet to be offered through the traditional health care system, it could be said that these companies offer services that are not necessarily included in the scope of the existing clinical guidelines regarding minors. However, if we only consider tests already accepted in a clinical setting, can we expect these companies to follow established guidelines? According to DNA Direct's website ''a parent or guardian (…) may do any of the following things on behalf of his or her child: (…) (d) order genetic tests'' ( Table 2 ). The company adds that in this case ''The parent or guardian assumes full responsibility for ensuring that the information that it provides to DNA Direct about his or her child is kept secure and that When an individual requests participation in the Suracell Program, they must first certify that they are 18 years of age or older, and that they consent to supply Suracell with personal health information, such as their specimens and answers to the Suracell Environmental and Lifestyle Questionnaire.
the information submitted is accurate'' ( Table 2 ). If they are indeed strictly following this policy, it would conflict with existing professional guidelines as they are providing, among other tests, genetic tests for breast cancer (BRCA1, BRCA2). This being said, due to the limitations of a web based analysis, it is impossible to ascertain exactly how this company would react if a parent were to order BRCA testing for their child in reality. After all, this company does require that consumers contact a company counselor before ordering BRCA testing, and therefore, it is possible that a parental request for a child to be tested could be denied at this stage regardless of what is written on their website. Moreover, DNA Direct underlines that they are operating ''according to the standards and guidelines of the National Society of Genetic Counselors and the American College of Medical Genetics, using board-certified personnel under the supervision and authorization of a physician'' [19] . Both professional bodies hold a clear position on testing in minors. The American College of Medical Genetics states that ''If the medical or psychosocial benefits of a genetic test will not accrue until adulthood, as in the case of carrier status or adult-onset diseases, genetic testing generally should be deferred. Exceptions to this principle might occur when the adolescent meets conditions of competence, voluntariness, and adequate understanding of information'' [20] . The National Society of Genetic Counselors states that when possible, as in the case of late-onset disorders, ''the child should be involved in the decision about whether or not to be tested'' [21] . This type of ambiguity concerning which policy is being followed should be reduced to a minimum and private companies offering genetic tests directly to consumers should be explicit about which standards they are adhering to, particularly with respect to testing in minors.
As alluded to previously, in view of the major ethical considerations that surround predictive genetic testing and carrier testing in minors, one could question whether the same guidelines apply for tests that are described by companies as not being for the purpose of preventing, diagnosing or treating medical conditions. It is interesting to note that many companies offering DTC genetic testing declare that their services are not clinical services and should not be used as a basis for making medical decisions. For example, Consumer Genetics writes in its Authorization and Disclosure form that ''all materials and products provided by Consumer Genetics, Inc. are provided for informational purposes only and are not by themselves intended for diagnosis or treatment of any disease or disorder'' [22] . The privacy policy found on iGenix, Inc's website describes that its ''service is not a test or kit designed to diagnose disease or medical conditions. Information you receive from the iGenix, Inc. service is not intended to be medical advice'' [23] . Likewise, 23andme emphasizes in its Terms of Service that their ''service content is not to be used, and is not intended to be used, by you or any other person to diagnose, cure, treat, mitigate or prevent a disease or other impairment or condition, or to ascertain your health'' [24] .
Various companies state that the predictive value of their genetic tests is insufficient as a useful basis for personalized nutritional and lifestyle recommendations. It remains, however, a possibility that consumers will overestimate the predictive value of the genetic tests [25] . Knowledge of an increased disease risk may affect the relationship between parents and children, and engender in the parents a sense of responsibility both for the disorder itself and for protecting the infant from its impact [26] . Excessive attention to genetic risk information could also decrease the attention to non-genetic factors in disease development and lead to an overestimation of (non-validated) risk information [27] .
Moreover, by accepting children's samples submitted by their parents, some companies are neglecting some of their own positions with regard to the sensitive and private character of genetic information. SeqWright states that ''your genetic information is extremely sensitive. In fact, it may be the most sensitive information there is and as new discoveries are made, and more is learned about what your genes say about you, this information is likely to become evermore sensitive over time'' [28] . deCODE claimed that ''the only people who should be able to see your genetic information are you and those with whom you choose to share it'' [29] . Contrary to the latter two companies, which do provide testing in children, it was precisely because of these ''ethical, privacy and informed consent considerations regarding genetic testing of minors for predisposition or carrier status of adult-onset genetic disorders'' [30] that Navigenics decided not to process samples or information from children who have not reached the age of majority.
The Human Genetics Commission (HGC) also raised the issue that any genetic testing service ''that requires a sample to be collected at home or to be tested by the consumer at home runs the risk of samples being submitted for testing without proper consent'' [31] . Therefore, it recommended that companies elaborate mechanisms to prevent non-consensual testing. During focus groups undertaken in preparation of the HGC report, particular concern was raised about how a company would be able to verify that a subject had consented to the test [32] . The HGC also supports the recommendations of the Advisory Committee on Genetic Testing's Code of Practice (1997) [33] which promotes the practice of not supplying genetic testing services direct-to-the-public to those under the age of 16 or to those not able to make a competent decision regarding testing.
The sale of clinically unvalidated genetic tests, as is done by many companies whom acknowledge this, to adults is controversial. It becomes more controversial when these tests are being sold to adolescents or minors who are not able to decide for themselves. Companies that are selling clinically validated tests should adhere to all professional standards and guidelines and should be offering the same quality of services as someone would expected in a centre for clinical genetics.
Finally, it is interesting, yet perhaps not completely unexpected, that while some companies' websites do not explicitly elaborate a policy about whether or not they test children upon parental request, they do take the time to explain to whom their website is directed or not directed. Cygene's website, for example, clearly states that ''You should also be aware that this website is not intended for, or designed to attract, individuals under the age of 18.'' DNA Direct underlines that their services are not ''designed or intended to attract children under the age of 13.'' The age of 13 can be explained by the fact that in the USA specific regulations (i.e. the Children's Online Privacy Protection Act) and guidelines (i.e. CARU guidelines for interactive media) apply to advertisements that are directed to children under the age of 13.
Finally, it is clear that our web-based method of analysis poses limitations to knowing what companies are really doing when faced with a request to test a child. This is true for all companies, regardless of the categories in which they have been classified. Furthermore, simply because a company's website does not include any information regarding testing in minors, this does not necessarily exclude the possibility that they do have a sound policy. In this regard, further research is necessary in which companies are directly approached in order to collect data regarding the number of tests they actually perform on children, and to compare if the position found on their webiste fully reflects what is done in practice. Moreover, the fact that this article only focuses on DTC genetic testing in children does not imply that there are no concerns regarding testing in adults. As was briefly mentioned in the introduction, this type of DTC service has raised a number of questions and concerns regarding many aspects of testing, including the clinical validity and utility of the tests.
Conclusion
We have analyzed the websites of 29 companies which sell health-related genetic tests directly to consumers. Many of these companies have not integrated a clear policy on their website regarding whether or not they would process samples coming from minors. It would be responsible for, at least, the companies selling genetic tests also offered in a clinical setting, to consider how to incorporate standards established by professional guidelines. This being said, even for genetic tests that are described as 'not being services which should be used to make medical decisions', the same best interest considerations, respect for autonomy, confidentiality and privacy suggest that children should not be tested unless there are immediate benefit for the child.
